Name: #AskDrDurie: Should Patients With Similar Types of Myeloma Form Separate Support Groups?
Uploaded: 2015-10-20T10:06:40-0700
Duration: 56 s
Description: This week Dr. Durie answers the question "Should Patients With Similar Types of Myeloma Form Separate Support Groups?"

This week Dr. Durie answers the question "Should Patients With Similar Types of Myeloma Form Separate Support Groups?"

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Dr. Paul Richardson's ASH Abstract on ICARIA-MM

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM)

ASH 2022

Bone Health and Multiple Myeloma

#AskDrDurie: In light of Tom Brokaw's recent myeloma diagnosis, is better early screening required?

#AskDrDurie: If Myeloma is Diagnosed, Is It Okay to Start With A Holistic Type of Approach First?

Share On

Donation

#AskDrDurie: Should Patients With Similar Types of Myeloma Form Separate Support Groups?

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM)

Bone Health and Multiple Myeloma

Give Where Most Needed